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Abstract
Abnormal uterine bleeding (AUB) is a chronic, debilitating and common condition 
affecting one in four women of reproductive age. Current treatments (conservative, 
medical and surgical) may be unsuitable, poorly tolerated or may result in loss of fertility. 
Selective progesterone receptor modulators (SPRMs) influence progesterone-regulated 
pathways, a hormone critical to female reproductive health and disease; therefore, 
SPRMs hold great potential in fulfilling an unmet need in managing gynaecological 
disorders. SPRMs in current clinical use include RU486 (mifepristone), which is licensed 
for pregnancy interruption, and CDB-2914 (ulipristal acetate), licensed for managing AUB 
in women with leiomyomas and in a higher dose as an emergency contraceptive. In this 
article, we explore the clinical journey of SPRMs and the need for further interrogation of 
this class of drugs with the ultimate goal of improving women’s quality of life.
Introduction
Selective Progesterone Receptor Modulators (SPRMs) 
are a class of synthetic steroids with different molecular 
structures. They interact with the progesterone receptor 
(PR) and may exert an agonist, antagonist or a mixed 
response (Lusher et  al. 2011). Progesterone plays a vital 
role in the structure, function and regulation of the female 
reproductive tract, including pregnancy. Progesterone 
mediates its function by interacting with the PR, a 
member of a superfamily of almost 50 ligand-activated 
nuclear transcription factors (McEwan 2009).
A large number of gynaecological problems such as 
abnormal uterine bleeding (AUB), fibroids (leiomyoma), 
adenomyosis, endometriosis and reproductive tract 
cancers are hormonally mediated; therefore, SPRMs hold 
great potential for the management of women with 
gynaecological disorders.
History of SPRMs
The search for drugs that modify progesterone activity 
with an aim to achieve contraception can be traced 
back to the 1960s (Pincus 1960). The first SPRM, RU486 
(mifepristone), was discovered in the 1980s, during 
the quest for discovery for anti-glucocorticoid drugs 
(Moguilewsky & Philibert 1984).
Several SPRMs have been developed (Fig. 1) since, 
and the latest in this class of drugs is vilaprisan. The 
development of SPRMS is shown in the timeline in Fig. 1.
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Non-steroidal SPRMS aim to achieve the effect of 
progesterone receptor binding that can selectively act 
as a progestin in the endometrium while acting as an 
antiprogestin within the leiomyoma; however, there is 
a limited clinical translation of these agents (Catherino 
et al. 2010).
Clinical need for SPRMs
Heavy Menstrual Bleeding (HMB) affects one in four 
women of reproductive age. It accounts for over a million 
annual referrals to the gynaecology services in the United 
Kingdom (UK) (Shapley et  al. 2004, Royal College of 
Obstetricians and Gynaecologists 2014). The effects of 
HMB may be so profound that the National Institute 
for Clinical Excellence (NICE 2018) defines HMB as any 
bleeding that negatively impacts the woman’s physical, 
emotional, social and/or material quality of life (NICE 
2018). This definition steers us away from the traditional 
definition (now only used in a research context – 
menstrual blood loss over 80 mL/cycle) of quantitatively 
estimating blood loss to define HMB (Hallberg & Nilsson 
1964, Warner et al. 2004).
HMB is also associated with economic implications 
for the healthcare system and loss of productivity due to 
time off work and presenteeism. Medical treatments may 
be ineffective, unsuitable or have undesirable side effects 
for some women. Surgical treatments for HMB may be 
invasive and may have associated surgical and anaesthetic 
risks and may cause a permanent loss of fertility for 
women (Frick et al. 2009).
A recent review using the data derived from the 
National HMB Audit (England and Wales) included 
nearly 15,000 women. The data showed that 54% of 
women seeking HMB treatment were under 45 years, with 
approximately two-thirds having no other co-morbidity. 
Half of the women under 45 years received fertility-ending 
surgery (hysterectomy or endometrial ablation) in the first 
year of referral to secondary services (Geary et al. 2019). 
However, given over half of all UK-born babies (55%) are 
to women aged 30 or older, fertility-ending surgery is not 
always acceptable (Office for National Statistics 2017). A 
recent Dutch study based on an internet survey of nearly 
43,000 women suggested that because of menstrual 
symptoms, nearly 38% of women reported being unable 
to perform their regular daily activities (Schoep et  al. 
Figure 1
Key points in the of the development of SPRMs (timeline) and current clinical significance. Mifepristone and ulipristal acetate are the only SPRMs in 
current clinical use. The use of Asoprisnil was halted due to concerns regarding endometrial changes (Guo & Groothuis 2018, Lewis et al. 2018). 
Telapristone studies were halted due to liver toxicity concerns (Lewis et al. 2018).
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2019). There remains an unmet clinical need in managing 
women with HMB.
The role of SPRMs in emergency contraception is well 
established. Further exploration is ongoing to investigate 
the role of SPRMs as an oestrogen-free method of long-
term contraception.
This article focuses on the SPRMS in current clinical 
use or undergoing investigation in clinical trials (Fig. 1).
Ulipristal acetate (UPA or CDB-2914 
or VA-2914)
UPA was first studied in the 1990s in the context of an 
‘antifertility’ drug in keeping with the properties of RU486 
(mifepristone), both in rats and humans (Passaro et  al. 
1997, Reel et al. 1998). Like mifepristone, UPA was labelled 
an ‘antiprogestin’ when initially developed and only in 
recent years has been classed as an SPRM. UPA is a steroidal 
SPRM with a structure of a 19 norprogesterone derivative: 
17a–Acetoxy-11b-(4-N, N-Dim ethyl amino pheny l)-19 -norp 
regna -4-9- diene -3,20 dione, also known as CDB 2914, 
since it was initially developed by the National Institute 
of Child Health and Human Development (NICHD). It is 
also known as HRP 2000 or VA 2914 (Bouchard 2014). The 
chemical structure of UPA is illustrated in Fig. 2.
Emergency Contraception (EC) Overview 
(United Kingdom)
UPA is United States Food and Drug Administration (US 
FDA) approved as an emergency contraceptive and is 
licensed in the United Kingdom for this purpose, including 
for over the counter (OTC) use (European Consortium 
for Emergency Contraception 2017). Evidence suggests 
that the most effective emergency contraceptive is a 
Copper intrauterine device (Cu-IUD). It has a failure rate 
of <1% when inserted within 5 days (120 h) after the 
first unprotected sexual intercourse (UPSI) in a natural 
cycle or within 5 days after the earliest estimated date 
of ovulation (whichever is later). The Faculty of Sexual 
and Reproductive Healthcare (FSRH) suggests it has the 
added advantage of providing ongoing contraception 
(Cleland et al. 2012, The Faculty of Sexual & Reproductive 
Healthcare 2017). There are limitations of using an IUD 
for this purpose; it cannot be used in women with an 
active pelvic infection, undiagnosed genital tract bleeding 
or distortion of uterine anatomy. It requires a medical 
professional available for insertion. Ongoing risks include 
that of uterine perforation, abnormal uterine bleeding 
and dysmenorrhoea in some users.
Other emergency contraceptive methods licensed in 
the United Kingdom include oral levonorgestrel (LNG) 
and oral UPA. LNG is used in a dose of 1.5 mg orally 
(single dose) and is licensed for use up to 72 h after UPSI 
or contraceptive failure. UPA is used in a dose of 30 mg 
and is licensed for up to 120 h for the same indications 
(The Faculty of Sexual & Reproductive Healthcare 2017). 
Current evidence suggests that UPA is more effective than 
LNG as an emergency contraceptive (Glasier et al. 2010, 
Shen et al. 2019).
The combined hormonal ‘Yuzpe method’ is no 
longer recommended for use in the United Kingdom, 
as evidence suggests lower efficacy as compared to LNG 
EC alone (Cheng et  al. 2012, Leung et  al. 2016). The 
oestrogen–progestin regimen comprises two doses of a 
combination of 100 μg of ethinyl oestradiol and 0.5 mg of 
levonorgestrel each, the first dose taken within 72 h after 
intercourse and the second 12 h later (Yuzpe & Lancee 
1977, Glasier 1997). There is a current lack of evidence 
to recommend the LNG-IUS as a method of emergency 
contraception (The Faculty of Sexual & Reproductive 
Healthcare 2017).
UPA and Emergency Contraception (EC)
The predominant mechanism of action of UPA is 
inhibition or delay of ovulation by interrupting the 
luteinising hormone (LH) surge (Stratton et  al. 2000). 
However, even when the LH surge has commenced, UPA 
can prevent ovulation, suggesting a direct effect on the 
growing ovarian follicle (Nallasamy et al. 2013).
In addition to inhibition of ovulation, endometrial 
effects (molecular) of UPA are also proposed, which may 
impact decidualisation and consequently implantation 
Figure 2
Chemical structure of UPA.
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(Lira-Albarran et al. 2018). Endometrial effects have also 
been proposed at a macroscopic level (Stratton et  al. 
2000, 2010, Passaro et al. 2003). Hence, UPA may be both 
contraceptive and contragestive in its actions, making it 
an effective emergency contraceptive (Keenan 2011).
This effect has been questioned in more recent 
reviews. Authors propose that the endometrial effects 
seen with UPA use may simply reflect a consequence of 
a delay in ovulation or require fairly large doses of UPA 
which are not currently used for UPA-EC (Li et al. 2019).
UPA and long-term contraception
Given the beneficial effects of UPA as an EC, its role as a 
long-term contraceptive has been explored in the form 
of a contraceptive vaginal ring (Jensen 2013). The study 
suggested that at a dose of 2500 µg/day, ovulation could 
be suppressed in up to 86% of treatment cycles assessed by 
transvaginal ultrasound and a hormonal assay. Progesterone 
receptor modulator associated endometrial changes (PAEC) 
were seen in nearly 79% of participants; however, PAEC 
were resolved upon UPA discontinuation (Huang et  al. 
2014). Further investigation is needed to elucidate the role 
of UPA as a long-term oestrogen free contraceptive.
UPA and fibroids (leiomyomas)
UPA is the only SPRM specifically approved and 
commercialised to date for management of symptomatic 
uterine fibroids. UPA controls HMB in over 90% of 
women, with an overall decrease in bleeding similar to 
Gonadotrophin releasing hormone (GnRH) agonist use. It 
has a faster onset of amenorrhoea, usually within 10 days. 
Oestradiol levels are maintained in the mid-follicular 
phase range during treatment, thereby reducing the 
likelihood of menopausal symptoms. Revised European 
Medicines Agency (EMA) and Medicines and Healthcare 
Products Regulatory Agency (MHRA) guidance should be 
used to guide UPA use (Table 1).
UPA and liver function
UPA was licensed for use in the UK and EU in 2012 
for the management of fibroids related HMB. During 
post-marketing surveillance of women exposed to UPA 
(approximately 765,000), eight cases of serious liver 
injury were identified, and of these cases, four required a 
liver transplant (https ://ww w.ema .euro pa.eu /en/d ocume 
nts/v ariat ion-r eport /esmy a-h-c -2041 -a20- 0043- epar- asses 
sment -repo rt-ar ticle -20_e n.pdf last accessed: 08/08/2018). 
This meant the use of UPA was temporarily halted for 
investigation. After considering all the evidence, in May 
2018, the Pharmacovigilance Risk Assessment Committee 
(PRAC) of the EMA concluded that UPA may have 
contributed to the development of some cases of serious 
liver injury; however, the status of UPA as a medication 
responsible for drug-induced liver injury (DILI) was not 
fully confirmed (European Medicines Agency 2018). 
UPA was reintroduced with clinical restrictions and liver 
function monitoring (Table 1).
UPA does not belong to any of the drug classes 
commonly considered as drug-induced liver injury 
agents, nor has it any molecular features similar to other 
drugs in the DILI network (Donnez et  al. 2018a). The 
current understanding is that UPA may be responsible 
for idiosyncratic (rather than intrinsic) DILI and that the 
use of liver health monitoring will help to minimise risks 
associated with its use (Donnez 2018).
Table 1 Current indications and restrictions of use of UPA in the United Kingdom and Europe (adapted from European 
Medicines Agency 2018, Medicines and Healthcare Products Regulatory Agency 2018).
Indications Liver function monitoring
UPA is indicated for the intermittent treatment  
of moderate to severe symptoms of uterine  
fibroids in women of reproductive age who are  
not eligible for surgery
Before initiation of each treatment course: perform liver function 
tests; do not initiate UPA in women with baseline alanine 
transaminase (ALT) or aspartate aminotransferase (AST) more 
that two times the upper limit of normal (ULN).
UPA is indicated for one course of preoperative treatment  
of moderate to severe symptoms of uterine fibroids in  
adult women of reproductive age
During the first two UPA treatment courses: perform liver function 
tests every month.
UPA treatment is to be initiated and supervised by a  
physician experienced in the diagnosis and treatment  
of uterine fibroids
For further treatment courses: perform liver function tests once 
before each new course and when clinically indicated.
UPA is contraindicated in women with underlying liver  
disorders
At the end of each treatment course: perform liver function tests 
after 2–4 weeks. Stop UPA treatment and closely monitor women 
with ALT or AST more than three times the upper limit of normal; 
consider the need for specialist hepatology referral.
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From the clinician’s perspective, review of the 
available clinical trial data suggests there were no cases in 
the 5 mg once daily (OD) UPA group (approved clinical 
dose) showing any liver enzymes outside accepted ranges 
(Donnez 2018, Donnez et al. 2018a).
Abnormalities in liver function tests have also 
been previously noted with the use of SPRMs including 
mifepristone and proellex (CDB-4124). All of these 
compounds have the 4-(dimethylamino) phenyl group 
in common. This structural element is accessible to 
metabolic demethylations, which may lead to the 
formation of aniline metabolites that have been reported 
to cause undesired effects in the liver by the formation 
of reactive intermediates (Lu et al. 2015). The data from 
clinical studies with SPRMs lacking the dimethylamino 
phenyl group, for example, lonaprisan, have provided no 
evidence of a clinically relevant, drug-related change in 
liver enzyme activity (Möller et al. 2018).
UPA and clinical trials
The majority of the clinical evidence for use for UPA in 
management of women with heavy menstrual bleeding 
and fibroids is available from the PGL4001 (ulipristal 
acetate) Efficacy Assessment in Reduction of symptoms 
due to uterine Leiomyomata, PEARL (four phase three 
trials; PEARL I–IV), and Assessment of Endometrial Safety 
During Treatment of Symptomatic Uterine Fibroids With 
Ulipristal Acetate, VENUS (I–II) trials (Donnez et  al. 
2012a,b, 2014, 2015, Illingworth et al. 2018, Simon et al. 
2018) (Table 2).
The PEARL trials and VENUS trials differed in that; the 
PEARL trials were conducted in European Centres with a 
subset of participants that was predominantly Caucasian 
and had a strict BMI cut-off. The VENUS trials were 
conducted in the United States with a predominantly 
(70%) African American population of participants and 
no BMI cut-offs. As with the PEARL trials, VENUS trials 
also supported the meaningful positive impact of UPA on 
women’s quality of life (Lukes et al. 2019).
Real-world data are also available from an observational 
study – the A Prospective Multicenter Non-interventional 
Study of Women Treated With ESMYA (ulipristal acetate) as 
Preoperative Treatment of Moderate to Severe Symptoms 
of Uterine Fibroids (PREMYA) study involving 1473 
women. Participants in this study received a 3-month 
course of 5 mg of UPA preoperatively. Only 38.8% of 
patients underwent surgery, mostly of a conservative/
minimally invasive nature, and there were clinically 
relevant improvements in pain and health-related quality 
of life (HRQoL) scores (Fernandez et al. 2017).
UPA and endometrial changes
SPRMs have a progesterone antagonist effect and when 
used clinically there is a theoretical risk of unopposed 
endometrial oestrogen exposure and subsequent 
endometrial hyperplasia or cancer due to progesterone 
antagonism with use of SPRMs. Progesterone Receptor 
Modulator Associated Endometrial Changes (PAEC) are 
a spectrum of morphological endometrial effects seen 
with SPRM use, that is, representing a class effect with the 
use of the drugs. PAEC histology characteristically shows 
cystically dilated glands with non-physiological secretory 
appearances, inactive epithelium and few mitotic figures, 
in a background of a compact non-decidualised stroma 
(Williams et al. 2012) (Fig. 3).
UPA administration has been shown to affect the 
expression and localisation of endometrial sex steroid 
receptors, modulate progesterone-responsive genes and 
to reduce endometrial cell proliferation (Whitaker et  al. 
2017). There is limited information available on the impact 
of SPRMs, such as UPA on the human endometrium at the 
molecular/cellular level.
A recent systematic review has examined the 
endometrial effects of UPA use in ten studies involving 1450 
women. The review supports the current understanding 
of PAEC; that it is essentially a benign condition, and 
reversible on discontinuation of UPA use. Most studies, 
however, have a limited follow-up period and have used 
UPA in up to four intermittent courses, so further research 
is needed before assuming that SPRMs including UPA are 
safe for long-term use (De Milliano et al. 2017).
UPA and fibroids (morphological changes)
UPA is known to have proapoptotic, antifibrotic and 
antiproliferative effects on uterine fibroids (Xu et  al. 
2005, Courtoy et al. 2015, Donnez et al. 2018b). This is 
significant clinically, as fibroids treated with UPA that have 
reduced in size do not increase in size immediately after 
discontinuation of UPA use, unlike after treatment with 
GnRH agonists, where fibroid growth may recommence as 
early as 4 weeks following cessation of treatment (Donnez 
et al. 2012b).
UPA also alters the expression of angiogenic proteins, 
such as vascular endothelial growth factor, and reduces 
the amount of extracellular matrix by increasing matrix 
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metalloproteinase (MMP) expression (Xu et al. 2008, Cox 
et al. 2018).
UPA and surgery
There is good quality evidence to support the use of GnRH 
agonists preoperatively in women with uterine fibroids. The 
potential advantages include the reduction in fibroid and/
or uterine size or volume, improvement in intraoperative 
blood loss, correction of pre-existing anaemia and the 
possibility of using more conservative approaches (e.g. 
vaginal hysterectomy) rather than a midline incision 
(Lethaby et  al. 2002). The major disadvantage of using 
GnRH analogues for 3–4 months preoperatively is the 
risk of side effects – predominantly hot flushes and night 
sweats – due to oestrogen withdrawal. UPA has been 
compared to GnRH agonists for this purpose and found to 
have similar efficacy in controlling uterine bleeding and 
having reduced side effects (10% vs 40%) (Donnez et al. 
2012b).
UPA is known to have proapoptotic, antifibrotic 
and antiproliferative effects on uterine fibroids with 
myometrial sparing (Gaillard et  al. 1985, Xu et  al. 
2005, Courtoy et al. 2015, Donnez et al. 2018b). UPA is 
thought to also effect the fibroid pseudocapsule, which 
in turn is proposed to make surgical planes challenging 
to identify and subsequently result in difficult fibroid 
enucleation (Mallick et  al. 2019). The pseudocapsule is 
a fibro-neurovascular structure surrounding the fibroid 
and separating it from the surrounding myometrium. In 
performing an ‘intracapsular myomectomy’, the fibroid 
is dissected from its pseudocapsule by breaking the 
connective tissue (fibrous) bridges (Tinelli et  al. 2012b). 
An intracapsular myomectomy is recommended as it 
may subsequently reduce the risk of recurrence, uterine 
rupture and adhesion formation (Tinelli et al. 2012a). The 
distortion of the pseudocapsule with UPA use in some 
cases may increase the difficulty in correctly identifying 
the surgical planes between the fibroid and its surrounding 
pseudocapsule, making an intracapsular myomectomy 
challenging to perform.
Several clinical trials have evaluated the role of UPA 
prior to myomectomy and have differing outcomes. The 
MYOMEX trial (ulipristal acetate vs gonadotropin‐releasing 
hormone agonists prior to laparoscopic myomectomy) is 
a small randomised controlled trial (RCT) (n = 55) that 
compared GnRH analogues (leuprolide acetate 11.25 mg 
i.m. single dose + oral placebo tablet OD for 12 weeks) vs 
UPA (5 mg OD for 12 weeks + i.m. saline placebo injection) 
prior to a laparoscopic myomectomy. Women treated with 
UPA had higher intraoperative blood loss, longer suturing 
times for the first fibroid and the myomectomies were 
perceived to be subjectively more difficult (de Milliano 
et  al. 2020). The MYOMEX trial was underpowered and 
included a very small number of women. Larger well-
designed RCTs are needed before conclusions regarding 
the use of UPA prior to myomectomy procedures may be 
drawn. Another recent small (n = 10 UPA; n = 52 no pre-
treatment) retrospective study in the United Kingdom 
supported the findings of potentially difficult laparoscopic 
myomectomy with UPA use (Mallick et al. 2019).
However, a recent systematic review which did not 
include the previously mentioned studies concluded that 
UPA is a suitable pre-treatment prior to both, hysteroscopic 
and laparoscopic myomectomies (Ferrero et al. 2019). The 
results must be interpreted with caution as the studies 
included are predominantly retrospective or prospective 
observational studies.
Figure 3
Haematoxylin and Eosin staining of the human endometrium in the proliferative phase (3A), secretory phase (3B) and following SPRM (UPA) treatment 
(3C) G: Endometrial Glands; S: Endometrial Stroma; L: Luminal Epithelium.
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UPA and endometriosis and adenomyosis
At the time of writing this review, we did not identify 
any RCTs evaluating the role of UPA in managing 
endometriosis and adenomyosis.
Endometriosis is a condition in which there is the 
presence of endometrial glands and stroma outside the 
uterus. It affects one in ten of women of reproductive age and 
is associated with pelvic pain, HMB and infertility (Eskenazi 
& Warner 1997, Missmer & Cramer 2003, Bedaiwy et al. 
2009). There is conflicting and limited evidence regarding 
the role of UPA in endometriosis. In animal models (rats 
with surgically induced endometriosis), UPA was found to 
induce regression and atrophy of the endometriosis lesions. 
This was accompanied by upregulation of proapoptotic 
markers, reduced cell proliferation and inflammatory 
markers (Huniadi et al. 2013). A case report by Bressler et al. 
described a significant reduction in endometriosis related 
refractory chronic pelvic pain, when treated with high dose 
UPA for 3 months (Bressler et al. 2017). In contrast, Donnez 
et al. described excellent response to UPA treatment when 
administered for two 3-month courses with regards to 
reduction in fibroid size; however, no effect on an ovarian 
endometrioma, with both conditions co-existing in the 
same patient (Donnez & Dolmans 2016). The current 
understanding is that endometriosis lesions occur as 
superficial endometriosis, deep infiltrating endometriosis 
(DIE) and ovarian endometriosis (endometriomas). The 
aetiopathogenesis of these subtypes is poorly understood 
and some authors consider them as distinct clinical 
and pathological entities. There is conflicting evidence 
on the response of endometriosis to UPA with no clear 
demarcation between the three subtypes, and therefore, 
further investigation in the form of well-designed RCTs is 
necessary.
Bird et al. defined adenomyosis as ‘the benign invasion 
of the endometrium into the myometrium, producing a 
diffusely enlarged uterus which microscopically exhibits 
ectopic, non-neoplastic, endometrial glands and stroma 
surrounded by the hypertrophic and hyperplastic 
myometrium' (Bird et  al. 1972). The prevalence of 
adenomyosis is difficult to ascertain because of a wide 
variation in diagnostic criteria both with imaging 
modalities and with histology. It has been estimated that 
histological confirmation of adenomyosis ranges from 5 
to 70% of patients who undergo hysterectomy (Abbott 
2017). With improvements in imaging technology, more 
cases of adenomyosis are now being diagnosed non-
invasively both using 2D and 3D pelvic ultrasonography 
and MRI (Bluhm & Dueholm 2019, Liu et al. 2019).
There is an emerging concept of ‘progesterone 
resistance’ in the pathogenesis of these hormone-
dependent conditions. In a normal cycling human 
endometrium, levels of the progesterone receptor (PR-
A, PR-B; 2 isoforms) increase under the influence of the 
oestrogen exposure in the follicular phase of the cycle and 
the levels of the oestrogen receptor (ER) also increase. After 
ovulation, the levels of ER decline under the influence of 
rising circulating progesterone concentrations. In women 
with endometriosis, reduced endometrial PR-A expression 
compared to eutopic endometrium and an absence of PR-B 
were reported (Attia et al. 2000). This is likely a contributing 
mechanism, whereby progesterone does not trigger the 
expression of the endometrial steroid metabolising enzyme, 
17 β hydroxysteroid dehydrogenase type 2 and subsequent 
metabolism of oestradiol (E2 - potent) to oestrone (E1 - less 
potent) (Bulun 2009, Bulun et al. 2010, Reis et al. 2013). 
Conversion of potent E2 to less potent E1, which normally 
occurs in the secretory phase endometrium, is regarded as 
a critical protective mechanism against oestrogen-induced 
growth. Moreover, endometrial expression profiling has 
documented dysregulation of progesterone-responsive 
genes in women with endometriosis (Taylor et  al. 1999, 
Aghajanova et al. 2010).
Polycystic ovary syndrome (PCOS) is the most 
common endocrinopathy affecting women of reproductive 
age. Women with PCOS present with diverse features 
which includes those involving the reproductive system, 
such as, irregular menstrual cycles, hirsutism, infertility 
and pregnancy complications, along with metabolic 
features (insulin resistance (IR), metabolic syndrome, 
prediabetes, type 2 diabetes (DM2) and cardiovascular risk 
factors (Monash University 2018). Although the concept 
of altered response to endogenous progesterone (P4), 
‘progesterone resistance’ has been addressed in the context 
of endometriosis, and it may be also evident in women 
with PCOS. A gene microanalysis by Savaris et al. reported 
that progesterone-regulated genes, including mitogen-
inducible gene 6 (MIG6), leukemia inhibitory factor (LIF), 
GRB2-associated binding protein 1 (GAB1), S100P and 
claudin-4, were significantly lower in the endometrium 
of women with PCOS, whereas cell proliferation genes, 
such as Anillin and cyclin B1, were up-regulated. These 
data lend support to the concept of progesterone 
resistance (Savaris et al. 2011). The altered expression of 
the isoforms of the progesterone receptor (PR-A, PR-B) 
and the downstream signalling pathways has also been 
proposed as a mechanism for progesterone resistance in 
women with PCOS; however, further discussion is beyond 
the scope of this review (Li et al. 2014).
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Mifepristone (RU-486)
The first SPRM, RU486 (mifepristone), was discovered 
in the 1980s, during the quest for discovery for anti-
glucocorticoid drugs (Moguilewsky & Philibert 1984) 
by the French pharmaceutical company Roussel-Uclaf. 
Mifepristone was synthesised by Georges Teutsch and is 
also referred as to RU-486, that is, RU-38486, the 38,486th 
compound synthesised by Roussel-Uclaf from 1949 to 
1980, which has been shortened to RU-486. The drug was 
subsequently trialled for pregnancy interruption after its 
antiprogestin properties were investigated by Étienne-
Émile Baulieu, a French endocrinologist and biochemist. 
Baulieu is often referred to as the ‘father’ of the abortion 
pill (Baulieu & Rosenblum 1991).
The chemical structure of mifepristone is shown in 
Fig.  4. It is a synthetic estrane steroid and its chemical 
name is 11β-(4-(dimethylamino) phenyl)-17α-(1-
propynyl) estra-4,9-dien-17β-ol-3-one.
SPRMs may have mixed progestational agonist and 
antagonist activity, which can be assessed by the McPhail 
test conducted in immature female rabbits. The test 
consists of administration of oestradiol benzoate (day 1 
to 6), followed by administration of the study drug (e.g. 
SPRM; day 7–12). Controls receive either the vehicle or 
oestradiol benzoate only. The rabbits are killed on day 
15, and the mid portions of the uteri are then analysed 
histologically to assess changes in the endometrium, which 
are subsequently scored. Using this test, mifepristone is 
classed as a ‘pure’ antagonist (McPhail 1934, Elger et al. 
2000, Chwalisz et  al. 2005); however, it must be noted 
that in the absence of progesterone, mifepristone has a 
partial agonist effect. The test is now rarely used (Fig. 5).
In addition to its effects on PR, mifepristone is also 
a potent anti-glucocorticoid and a weak antiandrogen. It 
has a significantly higher affinity to the glucocorticoid 
receptor (GR) as compared to the endogenous 
corticosteroid cortisol (ten times) or dexamethasone 
(three times) (Philibert et al. 1985, Baulieu 2013). The anti-
glucocorticoid actions are both centrally (ACTH feedback 
loop) and peripherally (via GR) mediated at doses >400 
mg/day, administered as a single dose (Bertagna et  al. 
1984, Gaillard et al. 1985). Mifepristone is reported to be 
devoid of oestrogenic, anti-oestrogenic, mineralocorticoid 
and anti-mineralocorticoid properties.
Mifepristone and pregnancy interruption
Mifepristone is the only SPRM that can interrupt 
pregnancy in several species, including humans, and 
is licensed for this purpose in several countries. The 
combination of mifepristone (usually 200 mg) and 
misoprostol, a prostaglandin analogue, is widely used 
for medical abortion in the first trimester (Cameron et al. 
1986, Rodger et al. 1989, Raymond et al. 2013). Most focus 
has been on offering medical abortions to women ≤63 
days of gestation, as these may be undertaken at home 
with great efficacy, safety and acceptability to women. 
This may be offered using a combination of 200 mg of 
oral mifepristone and vaginal or buccal misoprostol 
(Schaff et al. 2000, Chen & Creinin 2015).
More recent evidence also supports the role of using 
mifepristone-misoprostol for medical abortion from 64 to 
Figure 4
Chemical structure of mifepristone.
Figure 5
Spectrum of transition of progestational agonist to antagonist activity of 
SPRMS (PR: Progesterone Receptor). Progesterone is a pure PR agonist. 
Mifepristone is often classed (incorrectly) as a pure PR antagonist. The 
arrow demonstrates increasing levels of PR antagonism of the various 
SPRMs.
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70 days with a low rate of serious adverse events and high 
efficacy, also suitable in a ‘home setting’ (Hsia et al. 2019).
In the United Kingdom, the Royal College of 
Obstetricians and Gynaecologists (RCOG) suggests that 
medical abortion regimens using 200 mg oral mifepristone 
and misoprostol are effective and appropriate at any 
gestation, although as gestation increases, these would 
have to be undertaken in a medical facility (Royal College 
of Obstetricians and Gynaecologists 2011, National 
Institute for Health and Care Excellence 2019).
Mifepristone and fibroids
The first clinical human trial (n = 10) to determine 
the effects of mifepristone in women with fibroids 
was published in 1993 and revealed that 50 mg/day 
administered over a 3-month period could shrink fibroids 
and was well tolerated (Murphy et al. 1993). The same team 
subsequently demonstrated that 25 mg/day dosing was 
optimal for this purpose and induced ovarian acyclicity 
(Murphy et al. 1995).
Since then, several studies have been published 
demonstrating the benefits of using mifepristone in 
women with fibroids. A recent meta-analysis (11 RCTs and 
780 women) concluded that mifepristone significantly 
reduces uterine and fibroid (leiomyoma) volume and 
improves associated symptoms (HMB, dysmenorrhoea, 
pelvic pain, pressure and anaemia). The authors 
recommend 2.5 mg/day for 3 or 6 months as the optimum 
clinical treatment for uterine fibroids (leiomyoma). There 
is insufficient evidence to link its use to endometrial 
hyperplasia; however, monitoring of endometrial health 
should be undertaken (Shen et al. 2013).
In contrast, Cochrane (three RCTs and 112 women) 
concluded that mifepristone reduced HMB and improved 
fibroid-specific quality of life. However, it was not found 
to reduce fibroid volume and was associated with an 
increased risk of abnormalities in endometrial histology 
(Tristan et  al. 2012). The endometrial changes are 
indistinguishable from PAEC induced by other SPRMs 
(Fiscella et al. 2011). 
Mifepristone and Emergency Contraception
WHO defines ‘Emergency Contraception’ as methods of 
contraception that may be used to prevent pregnancy after 
sexual intercourse. The mechanism of action of mifepristone, 
however, depends upon its timing of administration in 
the menstrual cycle. When administered in the follicular 
phase, it prevents the LH surge and interrupts/delays 
ovulation (Spitz et al. 1996). If administered immediately 
at or after ovulation, it may block tubal motility and or 
blastocyst attachment or nidation as seen in vitro, that is, 
administration is contragestive rather than contraceptive 
(Lalitkumar et al. 2007).
Evidence suggests that mifepristone in a dose of 
10 mg used up to 120 h after UPSI is an effective emergency 
contraceptive (Piaggio et al. 2003a). A Cochrane review has 
also supported the use of mifepristone as an emergency 
contraceptive (Cheng et al. 2008).
Higher doses are associated with a delay in menstruation 
(with added stress and anxiety of potential pregnancy), 
vaginal bleeds within 5 days of oral mifepristone and 
fatigue, and hence, the preference for the use of lower 
doses (Task Force on Postovulatory Methods of Fertility 
Regulation 1999).
A meta analysis has evaluated the administration of 
mifepristone at doses between 5 mg and 600 mg for the 
purpose of emergency contraception. The pregnancy rate 
increases by a factor of 1.6 when the dose of 10 mg is 
used instead of 25 mg. In terms of the number of women 
needed to treat, however, using 10 mg in the place of 25 
mg implies having one extra pregnancy every 146 women 
requesting emergency contraception (Piaggio et al. 2003b).
Mifepristone and long-term contraception
The first human clinical trial (n = 21) using mifepristone 
as a long-term contraceptive utilised a 200 mg single dose 
48 h after an LH surge, determined by using urinary LH 
kits, with a treatment duration between 1 and 12 months. 
The endometrial effects were considered adequate to 
prevent pregnancy. The only major side effect was vaginal 
bleeding noted in a third of women, 2–3 days after 
treatment (Gemzell-Danielsson et al. 1993).
Evidence also shows that mifepristone at doses 2–5 
mg/day (up to 120 days) has the potential to suppress 
the LH surge and subsequently ovulation, providing 
contraception and inducing amenorrhoea (Brown et  al. 
2002). A small study compared the daily administration of 
mifepristone 5 mg/day (n = 73) vs levonorgestrel 30 µg/day 
(progesterone only pill; n = 23) for 24 weeks. Mifepristone 
was found to be an effective contraceptive with improved 
bleeding patterns; however, benign endometrial changes 
(now described as PAEC) were noted with 6 months of use 
(Lakha et al. 2007). Mifepristone has also been evaluated 
as a ‘once-monthly’ pill; however, the results as a reliable 
contraceptive have been disappointing (Narvekar et  al. 
2006).
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Mifepristone and endometriosis
The first human clinical studies using the drug for women 
diagnosed with endometriosis showed promising results. 
The drug was used in a dose of 100 mg/day for 3 months 
(Kettel et  al. 1991) or 50 mg/day for 6 months (Kettel 
et  al. 1996). In the higher dose, short-term use group, 
improvement in endometriosis symptoms were noted, 
but no regression of endometriotic lesions was seen at 
post-treatment laparoscopy. In addition, evidence of 
hypercortisolism was noted. In the subsequent study, 
using a lower dose for a long duration, in addition 
to symptomatic improvement and regression of 
endometriotic lesions, a clear dissociation from the anti-
glucocorticoid activity was noted.
Cochrane currently suggests that mifepristone 
improves endometriosis-associated dysmenorrhoea and 
potentially dyspareunia. Amenorrhoea is a common 
association and is classed as a ‘side effect’, although, lack 
of menstruation may be clearly beneficial in women with 
endometriosis-associated HMB. Doses <2.5 mg/day are 
less likely to be effective; however, based on the available 
evidence, clear conclusions on dosage cannot be made (Fu 
et al. 2017).
Mifepristone and use for non-
gynaecological indications
Although a full review of the non-gynaecological benefits 
of mifepristone is beyond the scope of this article, it has 
been explored and used in the clinical context for the 
indications discussed in the subsequent section.
Mifepristone has been explored as an anti-
glucocorticoid drug. This may particularly be of value in 
the medical treatment of Cushing’s disease; mifepristone is 
considered as an adjuvant drug in this regard (Carmichael 
& Fleseriu 2013). The drug also shows potential for treating 
neuropsychiatric disorders, mood disorders and Alzheimer’s 
disease (DeBattista & Belanoff 2006). Mifepristone has 
also been trialled in the management of inoperable 
meningiomas (Haak et al. 1990, Matsuda et al. 1994).
For its antiprogesterone properties, mifepristone has 
been evaluated in the management of breast cancers 
(Romieu et  al. 1987, Klijn et  al. 1989). Treatment with 
RU486 (mifepristone) has been shown to prevent 
mammary tumorigenesis in Brca1/Trp53-deficient mice 
(Poole et  al. 2006). The potential role of SPRMs in the 
prevention of breast cancer has been previously proposed 
(Bouchard et al. 2011).
Vilaprisan
Vilaprisan (BAY 1002670) is a more recent, potent, 
orally active SPRM. Vilaprisan was developed by and 
is the property of Bayer AG, Berlin, Germany. It is a 
17-hy droxy -17-p entafl uoro ethyl -estr a-4,9 (10)- dien-
11-aryl derivative. Vilaprisan can weakly bind to the 
glucocorticoid receptor and androgen receptor with 
no effect on the oestrogen receptor (Wagenfeld et  al. 
2013, Möller et al. 2018). Its chemical structure is shown 
in Fig. 6.
Clinical trials
The currently available information for vilaprisan is 
generated from human clinical phase I and II trials in 
women with HMB and fibroids (Bradley et al. 2016, Schütt 
et al. 2016, 2018, Schultze-Mosgau et al. 2017, 2018). The 
results of the first trials comparing vilaprisan vs ulipristal 
acetate vs placebo in a randomised, double-blind, 
parallel-group fashion (ASTEROID 2 study) have not been 
published at the time of writing this paper. The findings 
from these trials are listed in Table 3.
Vilaprisan has been undergoing clinical trials for 
management of HMB with uterine fibroids (ASTEROID 5; 
NCT Identifier: 03240523, ASTEROID 6; NCT Identifier: 
03194646 and ASTEROID 7; NCT Identifier: 03699176) 
and a phase 2B randomised placebo-controlled trial in 
managing women with symptomatic endometriosis (NCT 
Identifier: 03573336; VILLENDO Study). At the time of 
writing this article, all vilaprisan trials were on hold due 
to new safety findings in long-term toxicology study in 
rodents (Bayer 2018, Burger 2018).
Figure 6
Chemical structure of vilaprisan.
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Conclusion
SPRMs have been in development since the 1980s, and 
yet a perfect SPRM does not exist. The class of compounds 
do have some common effects, including suppression 
of the LH surge, anovulation, amenorrhoea and benign 
endometrial changes or PAEC. Some SPRMs have clear 
indications and therapeutic benefits, for example, 
mifepristone for pregnancy interruption and ulipristal 
acetate for emergency contraception and management of 
fibroid related HMB.
There still appears to be a great void in what SPRMs 
could achieve in terms of their therapeutic potential. There 
are few well-conducted RCTs which examine the role of 
SPRMs in endometriosis, adenomyosis or hormonally 
mediated chronic pain syndromes. For AUB alone, which 
is common (affecting one in four women of reproductive 
age) and debilitating, the role of SPRMs yet remains to 
be determined. The UCON study (Ulipristal vs Coil for 
the Management of Heavy Menstrual Bleeding; EudraCT: 
2014-003408-65) once completed may provide valuable 
insights as to the utility of SPRM (UPA) administration in 
women with and without fibroids. SPRMs may also offer 
the potential of long-term oestrogen free contraception 
with less unscheduled bleeding – the side effect occurring 
in 20% of users of progestin-only methods of contraception 
(Lethaby et al. 2015). Optimal routes for administration 
for contraceptive indications will also require evaluation.
The attractiveness of SPRMS lies in the fact that they 
may be orally administered but have the potential for local 
drug delivery, that is, via intrauterine or vaginal routes. 
They have the advantage of maintaining peripheral mid-
follicular oestradiol levels, avoiding hypo-oestrogenic 
side effects. From the perspective of the clinician, this 
means a class of drugs which may help in the medical 
management of common gynaecological pathologies 
without the side-effect profile of current standard medical 
treatments. From the academic perspective, very little is 
known about the endometrial mechanisms underpinning 
the development of PAEC and the long-term implications 
on the endometrial molecular signature.
These are reasons to further pursue research, 
development and undertake well-conducted clinical trials 
involving SPRMs with the ultimate goal of improving 
women’s health and their quality of life.
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